13 Aug 2018

ENOUGH IS ENOUGH: MEDICAL GROUPS DEMAND HHS STOP STALLING ON INFORMATION BLOCKING

                Enough is enough. The American Academy of Family Physicians (AAFP) joined 13 other medical associations and healthcare organizations Aug. 9 in telling the federal government it has dragged out the regulation-writing process on an important topic far too long. At issue are the information blocking provisions of the 21st Century

0
: https://www.veintherapynews.com/ex-employee-char…r-financial-gain/ ‎
10 Aug 2018

DON’T BE VEIN: INBOUND CALLS HAVE NEVER BEEN MORE VALUABLE TO YOUR PRACTICE

   By Bruno Tabbi The phone is going through a bit of a renaissance. Even almighty Google concedes that inbound calls to businesses are worth more than web leads, hence their push toward click-to-call. A recent <ital>Harvard Business Review <endital> article noted that calls convert to new business 10 to

0
10 Aug 2018

GLOBAL ULTRASOUND DEVICES MARKET ANALYZED THROUGH 2023

           A global ultrasound devices market report has added to the Research and Markets  offering. According to the “Global Ultrasound Devices Market — Segmented by Application, Technology, Type, and Geography – Growth, Trends, and Forecast (2018-2023)” report, the market is expected to register a CAGR of about 4 percent during 2018-2023. The

0
09 Aug 2018

METACTIVE TOUTS PERIPHERAL ARTERY RESEARCH RESULTS

Metactive Medical Inc., a Kansas medical device company developing products for the treatment of neurovascular and peripheral vascular diseases, announced today that Kieran Murphy, professor, vice chair and director of research in the department of Medical Imaging at the University of Toronto, presented new nonclinical results from Metactive’s peripheral vascular

0
08 Aug 2018

MEDICAL GROUPS SEE PROGRESS IN CMS’s EHR APPROACH IN HOSPITAL RULE

Medical groups have applauded steps that the Centers for Medicare & Medicaid Services took to ease administrative burden through a new rule on hospital payments, while still pressing the agency for further changes in its approach to electronic health records. On Aug. 2, the CMS unveiled the final version of

0
07 Aug 2018

MICROSOFT IS DEVELOPING A GLASSES-BASED BLOOD PRESSURE MONITOR

            Microsoft is developing new blood pressure monitoring technology called Glabella, which comes equipped on a pair of glasses that passively collects physiological data on the wearer, according to a research paper recently released by the company. The paper was written by Christian Holz, Microsoft Research in Redmond; and  Edward J.

0
05 Aug 2018

FIBER OPTICS HAS PAID ITS DUES IN MEDICAL IMAGING

    By Michael Dargie It would be hard to overstate the seismic role fiber optics technology has played in enabling the Internet Age. After all, fused silica fiber bundles are the medium of choice for carrying signals, data, and information over today’s omnipresent telecommunications, cable, and Internet networks. But

0
04 Aug 2018

HEALING AT THE MID-LEVEL: TWO MID-LEVEL PRACTITIONERS DISCUSS CHALLENGES, REWARDS, FUTURE OF THEIR PROFESSION

   By Larry Storer Mid-level practitioners in the medical field include occupations of nurse practitioners, nurse midwives, nurse anesthetists, clinical nurse specialists and physician assistants, to name a few. In this article, I asked two mid-level practitioners from American Vein & Vascular Institute to share their thoughts on the occupation,

0
01 Aug 2018

FIRST MR THEATER IN U.S. OPENS AT PARRISH HEALTHCARE IN FLORIDA

  Patients at the Parrish Healthcare Center in Titusville, Fla., are the first to have access to enhanced comfort during Magnetic Resonance (MR) exams thanks to the installation of the nation’s first Vantage Titan / Zen Edition 1.5T MR Theater from Canon Medical Systems USA Inc. The new MR theater projects peaceful, virtual reality

0
01 Aug 2018

GE HEALTHCARE, LANTHEUS BEGIN A PHASE 3 CLINICAL TRIAL OF FLURPIRIDAZ TO TREAT CAD

GE Healthcare and Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., have started a second Phase 3 clinical trial of Flurpiridaz 18F (called the AURORA study), an investigational agent being evaluated for the detection of coronary artery disease (CAD), the most common form of heart disease.1 CAD affects an estimated

0